Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Raymond James startet Coverage für Taysha Gene Therapies mit "Strong Buy"-Rating | 7 | Investing.com Deutsch | ||
Mo | Raymond James initiates Taysha Gene Therapies stock with Strong Buy rating | 3 | Investing.com | ||
TAYSHA GENE THERAPIES Aktie jetzt für 0€ handeln | |||||
Fr | Why Is Taysha Gene Therapies Stock Falling Friday? | 6 | Benzinga.com | ||
Fr | Astellas walks away from gene therapy pact with Taysha before pivotal trial launch | 6 | FierceBiotech | ||
Fr | I-Mab morphs into 'hub-and-spoke' biotech; Astellas passes on Taysha gene therapy | 7 | BioPharma Dive | ||
Fr | Taysha Gene Therapies regains full rights to TSHA-102 | 2 | Seeking Alpha | ||
Fr | Cantor Fitzgerald reiterates Overweight rating on Taysha Gene Therapies stock | 1 | Investing.com | ||
Fr | Cantor Fitzgerald bekräftigt "Overweight"-Rating für Taysha Gene Therapies und sieht erhebliche Unterbewertung | 2 | Investing.com Deutsch | ||
16.10. | Taysha regains full rights to Rett syndrome gene therapy program | 2 | Investing.com | ||
16.10. | Taysha Gene Therapies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
16.10. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome | 223 | GlobeNewswire (Europe) | The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic... ► Artikel lesen | |
13.10. | Taysha Gene Therapies: Citizens bestätigt "Market Outperform"-Rating wegen Potenzial bei Rett-Syndrom | 5 | Investing.com Deutsch | ||
09.10. | Taysha Gene Therapies, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
09.10. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting | 1 | GlobeNewswire (USA) | ||
03.10. | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 126 | GlobeNewswire (Europe) | DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
02.10. | Baird raises Taysha Gene Therapies stock price target to $12 on Rett syndrome study | 3 | Investing.com | ||
02.10. | Demystifying Taysha Gene Therapies: Insights From 6 Analyst Reviews | 4 | Benzinga.com | ||
02.10. | Rett-Syndrom-Studie: Baird hebt Kursziel für Taysha Gene Therapies auf 12 US-Dollar an | 2 | Investing.com Deutsch | ||
02.10. | Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday | 17 | Benzinga.com | ||
02.10. | Taysha soars on FDA breakthrough therapy status for lead asset | 4 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 91,20 | -0,49 % | Übernahmefieber und KI-Chance: BioNTech, Novo Nordisk, PanGenomic Health Aktie | Übernahmefieber im Pharma- und Biotech-Bereich. Novo Nordisk hat nach der angekündigten Milliardenübernahme in den USA den nächsten Deal gemeldet. Die Dänen sehen ein mögliches Best-in-Class-Therapeutikum... ► Artikel lesen | |
EVOTEC | 6,716 | -0,15 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
CUREVAC | 4,516 | -2,55 % | BioNTech startet milliardenschweres Umtauschangebot für CureVac-Aktien | BioNTech hat das öffentliche Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. gestartet. Das Angebot basiert auf dem Kaufvertrag vom 12. Juni 2025 und sieht vor, dass jede CureVac-Aktie... ► Artikel lesen | |
AMGEN | 255,90 | +0,31 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
NOVAVAX | 7,360 | +1,03 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
BIOGEN | 127,10 | -0,16 % | Biogen Inc.: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 | Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,980 | +3,12 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
MAINZ BIOMED | 1,500 | 0,00 % | Mainz Biomed reports on blood-based screening test for pancreatic cancer | ||
VIKING THERAPEUTICS | 28,200 | +4,27 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule
VK2735 Phase 1 Maintenance... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 21,990 | +3,87 % | Intellia (NTLA) Soars 13% to Fresh High | ||
TEMPUS AI | 75,50 | +2,72 % | AKTIONÄR-Tipp Tempus AI lässt Biotech-Aktie explodieren | Der Megatrend Künstliche Intelligenz (KI) ist an den Börsen weiter in aller Munde. Einer der großen Gewinner der Entwicklung: Tempus AI. Das Unternehmen will mit seinen KI-gestützten Lösungen die Präzisionsmedizin... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,536 | +5,51 % | Defence Therapeutics Inc.: Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025 | Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 6,084 | -0,20 % | BioCryst's $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE | ||
KUROS BIOSCIENCES | 33,940 | -1,74 % | Kuros erhöht nach den ersten neun Monaten das Umsatzziel | Schlieren - Das Medtechunternehmen Kuros zeigt sich nach den ersten neun Monaten zuversichtlicher betreffend der Umsatzentwicklung im Gesamtjahr 2025. Von Januar bis September erhöhte das Unternehmen... ► Artikel lesen | |
BIOMARIN PHARMACEUTICAL | 46,340 | +0,78 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism | New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission... ► Artikel lesen |